Novavax (NASDAQ: NVAX) reported Q3 EPS of ($0.12), $0.03 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $6.53 million versus the consensus estimate of $10.59 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.